The latest clinical breakthroughs, practice management updates, and national advocacy alerts directly from the American Academy of Ophthalmology.
Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration
To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (AMD).
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.